Opioids in chronic low back pain: A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration;Opioide bei chronischem Kreuzschmerz: Systematische Übersicht und Metaanalyse der Wirksamkeit, Verträglichkeit und Sicherheit in randomisierten, placebokontrollierten Studien über mindestens 4 Wochen

Schmerz

Volumn 29, Issue 1, 2015, Pages 60-72

  Petzke, F ^a   Welsch, P ^b   Klose, P ^c   Schaefert, R ^d   Sommer, C ^e   Hauser W ^f,g  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Stichting Rugzorg Nederland   (Netherlands)

^c KLINIKEN ESSEN MITTE   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g KLINIKUM SAARBRÜCKEN   (Germany)

Author keywords

Chronic low back pain; Meta analysis; Opioids; Systematic review

Indexed keywords

BUPRENORPHINE; HYDROMORPHONE; OPIATE; OXYCODONE; OXYMORPHONE; PLACEBO; TAPENTADOL; TRAMADOL; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ARTICLE; ATTRIBUTABLE RISK; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FUNCTIONAL STATUS; HUMAN; LOW BACK PAIN; META ANALYSIS; PAIN INTENSITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; CLASSIFICATION; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DAILY LIFE ACTIVITY; DRUG EFFECTS; LONG TERM CARE; PAIN MEASUREMENT; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ANALGESICS, OPIOID; CROSS-OVER STUDIES; HUMANS; LONG-TERM CARE; LOW BACK PAIN; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84925510165     PISSN: 0932433X     EISSN: 14322129     Source Type: Journal    
DOI: 10.1007/s00482-014-1449-8     Document Type: Article

References (43)

1. Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326(7382):219
2. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101
3. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2010) Nationale VersorgungsLeitlinie Kreuzschmerz – Langfassung. Version 1.X. http://www.versorgungsleitlinien.de/themen/kreuzschmerz. Zugegriffen: 15. August 2013
4. Chaparro LE, Furlan AD, Deshpande A et al (2013) Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev 8:CD004959
5. Chou R, Huffman LH (2007) Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 147(7):505–514
6. Chu LF, D’Arcy N, Brady C et al (2012) Analgesic tolerance without demonstrable opioid-induced hyperalgesia: a double-blinded, randomized, placebo-controlled trial of sustained-release morphine for treatment of chronic nonradicular low-back pain. Pain 153(8):1583–1592
7. Cohen J (1988) Statistical power analysis for the behavioral sciences. Lawrence Erlbaum Associates, Hillsdale
8. Egger M, Smith GD, Schneider M (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
9. Fayers PM, Hays RD (2014) Don’t middle your MIDs: regression to the mean shrinks estimates of minimally important differences. Qual Life Res 23(1):1–4
10. Gordon A, Rashiq S, Moulin DE et al (2010) Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Pain Res Manag 15(3):169–178
11. Guyatt GH, Oxman AD, Kunz R et al (2008) Going from evidence to recommendations. BMJ 336(7652):1049–1051
12. Häuser W, Bernardy K, Maier C (2014) Langzeitopioidtherapie bei chronischem nicht-tumorbedingtem Schmerz. Systematische Übersicht und Metaanalyse der Wirksamkeit und Risiken in offenen Langzeitanschlussstudien über mindestens 26 Wochen. Schmerz. dx.doi.org/10.1007/s00482-014-1452-0
13. Higgins JPT, Green S (o J) Cochrane Handbook for systematic reviews of intervention. Version 5.1.0. http://handbook.cochrane.org/
14. Kissin I (2013) Long-term opioid treatment of chronic nonmalignant pain: unproven efficacy and neglected safety? J Pain Res 6:513–529
15. Moher D, Liberati A, Teztlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 51:1–7
16. Moore AR, Eccleston C, Derry S et al (2010) „Evidence“ in chronic pain—establishing best practice in the reporting of systematic reviews. Pain 150(3):386–389
17. Moore RA, Derry S, Wiffen PJ (2013) Challenges in design and interpretation of chronic pain trials. Br J Anaesth 111(1):38–45
18. Moulin DE, Lezzi A, Amireh R et al (1996) Randomised trial of oral morphine for chronic non-cancer pain. Lancet 347(8995):143–147
19. Noble M, Treadwell JR, Tregear SJ et al (2010) Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 1:CD006605
20. O’Donnell JB, Ekman EF, Spalding WM et al (2009) The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, double-blind, 6-week studies. J Int Med Res 37(6):1789–1802
21. Pillastrini P, Gardenghi I, Bonetti F et al (2012) An updated overview of clinical guidelines for chronic low back pain management in primary care. Joint Bone Spine 79(2):176–185
22. Portenoy RK, Farrar JT, Backonja MM et al (2007) Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain 23(4):287–299
23. Reinecke H, Sorgatz H, German Society for the Study of Pain (DGSS) (2009) S3 guideline LONTS. Long-term administration of opioids for non-tumor pain. Schmerz 23(5):440–447
24. Review Manager (RevMan) [Computerprogramm]. Version 5.2. The Nordic Cochrane Centre, The Cochrane Collaboration, Kopenhagen, 2012
25. Schaefert R, Welsch P, Klose P et al (2014) Opioide bei chronischem Arthroseschmerz. Systematische Übersicht und Metaanalyse der Wirksamkeit und Risiken in randomisierten, placebokontrollierten Studien über mindestens 4 Wochen. Schmerz. dx.doi.org/10.1007/s00482-014-1451-1
26. Sommer C, Welsch P, Klose P et al (2014) Opioide bei chronischem neuropathischem Schmerz. Systematische Übersicht und Metaanalyse der Wirksamkeit, Verträglichkeit und Sicherheit in randomisierten, placebokontrollierten Studien über mindestens 4 Wochen. Schmerz. dx.doi.org/10.1007/s00482-014-1455-x
27. Turk DC, Wilson HD, Cahana A (2011) Treatment of chronic non-cancer pain. Lancet 377(9784):2226–2235
28. Von Korff M, Kolodny A, Deyo RA, Chou R (2011) Long-term opioid therapy reconsidered. Ann Intern Med 155(5):325–328
29. Vos T, Flaxman AD, Naghavi M et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2163–2196
30. Watson CP, Watt-Watson J, Chipman M (2010) The long-term safety and efficacy of opioids: a survey of 84 selected patients with intractable chronic noncancer pain. Pain Res Manag 15(4):213–217
31. Yarlas A, Miller K, Wen W et al (2013) A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain. J Pain 14(1):14–23
32. Buynak R, Shapiro DY, Okamoto A et al (2010) Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 11(11):1787–1804
33. Cloutier C, Taliano J, O’Mahony W et al (2013) Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study. Pain Res Manag 18(2):75–82
34. Gordon A, Callaghan D, Spink D et al (2010) Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther 32(5):844–860
35. Hale ME, Ahdieh H, Ma T, Rauck R (2007) Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomised, double-blind, placebo-controlled study. J Pain 8(2):175–184
36. Hale M, Khan A, Kutch M, Li S (2010) Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr Med Res Opin 26(6):1505–1518
37. Katz N, Rauck R, Ahdieh H et al (2007) A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin 23:117–128
38. Schnitzer TJ, Gray WL, Paster RZ, Kamin M (2000) Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol 27(3):772–778
39. Steiner DJ, Sitar S, Wen W et al (2011) Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naive patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J Opioid Manag 42(6):903–917
40. Uberall MA, Mueller-Schwefe GH, Terhaag B (2012) Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study. Curr Med Res Opin 28(10):1617–1634
41. Vondrackova D, Leyendecker P, Meissner W et al (2008) Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 9(12):1144–1154
42. Vorsanger GJ, Xiang J, Gana TJ et al (2008) Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. J Opioid Manag 4(2):87–97
43. Webster LR, Butera PG, Moran LV et al (2006) Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain 7(12):937–946